Merck’s anti-TL1A antibody from Prometheus buyout passes ph. 3 test in ulcerative colitis
Merck is making advances in the lucrative ulcerative colitis field with the key prize of its $11 billion buyout from several years ago.
Merck is making advances in the lucrative ulcerative colitis field with the key prize of its $11 billion buyout from several years ago.